PF-Atlas › Drugs › Mocetinostat

Mocetinostat

Idiopathic Pulmonary Fibrosis · Epigenetically unlocks fibroblasts from myofibroblast state

Mechanism
Epigenetically unlocks fibroblasts from myofibroblast state
Development stage
Phase II
Evidence level
Level 2 (Phase II)
Developer
Multiple

Overview

HDAC activity locks fibroblasts in activated state. Inhibition allows reversal to quiescent phenotype.

Explore related

Treatment profileEpigenetically unlocks fibroblasts from myofibroblast stateAll trialsResearch
Medical disclaimer. This page summarizes research about Mocetinostat for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.